Loading
A phase 2 trial of Atezolizumab, Fruquintinib in colorectal cancer, run by Kahr Bio Australia Pty Ltd, now recruiting.
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. is a phase 2 interventional study registered as NCT07235293 by Kahr Bio Australia Pty Ltd, with 90 participants planned, started 2026-01-16 and due to reach its primary completion in 2026-09-30. Interventions recorded: DSP107 + Atezolizumab, Fruquintinib. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors, Immune checkpoint inhibitors.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors, Colorectal cancer.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors, Immune checkpoint inhibitors.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors, Immune checkpoint inhibitors.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/